Can decreasing the serum level of CA19–9 predict the survival benefit of gemcitabine for advanced pancreatic cancer?

4208 Background: Serum carbohydrate antigen 19–9(CA19–9) is one of the useful marker for diagnosis of pancreatic cancer (PC), but its value for evaluating the survival benefit with Gemcitabine(GEM)...